# Jiuyou Capital

> Jiuyou Capital is a VC fund backing Biotechnology and Medical. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 16
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.jiuyoucapital.com.cn

Jiuyou Capital is a VC fund focused on Biotechnology and Medical. Jiuyou Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks and brokerages. Relying on the shared economy model of “Internet + Social + Finance”, Jiuyou Capital is committed to building a more optimized and efficient investment industryecosystem, and thus becomes China's most influential financial resource integration and service platform.

## Contacts

5 contacts available for Jiuyou Capital. Shizune tracks 1 team members at Jiuyou Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/jiuyou-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $14M–$43M |
| Series B | $2.8M–$41M |
| Series C | $2.8M–$142M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 50% |
| Medical | 4 | 25% |
| Health Care | 4 | 25% |
| Pharmaceutical | 4 | 25% |
| Biopharma | 2 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 25% |
| Series B | 4 | 25% |
| Series C | 3 | 19% |
| Angel | 2 | 13% |
| Funding Round | 2 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 11 | 69% |
| Taiwan | 1 | 6% |
| United States | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Sun Yi | Managing partner | 1 | https://shizune.co/investors/profile/sun-yi-9ac6 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jingxin Microelectronics | Jingxin Microelectronics is a developer of communication and information security chips including NRS1800, SDI3210, ESW5610, PRB0400 PCIe to SRIO and other chips and boards, enabling an efficient supply of high-speed data switching chips for the industry market. | $13.8M | Series B | May 20, 2024 |  |
| ReLive Biotechnologies LTD | ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science. | $43M | Series A | Jan 16, 2023 |  |
| Maijing Gene | Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine.Maijing Gene was established in 2015 and is based in Guangzhou,China. |  | Series C | Dec 29, 2022 |  |
| Jisi Yingda | Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development. |  | Series B | Nov 15, 2021 |  |
| OakMega | OakMega is a provider of cross-platform CRM solutions on messaging apps for marketing experts. Driven by honest values, and win-win mentality in their culture, OakMega is out to connect brands and people with human touch. |  | Series A | May 10, 2021 |  |
| Sinovent | Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. |  |  | Dec 31, 2020 |  |
| Zenshine Pharma | Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases. | $15M | Series A | Dec 01, 2020 |  |
| Sinovent | Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $144.7M | Series C | Aug 25, 2020 |  |
| SmartNuclide | SmartNuclide is a biopharmaceutical company that develops biological drug products. | $2.8M | Series B | Apr 23, 2020 |  |
| Linpowave | Linpowave specializes in the research and development of millimeter-wave radar detection systems. | $7.1M |  | Nov 27, 2019 |  |

10 of 16 investments shown.

## Co-investors
- [Indaco Capital](https://shizune.co/investors/profile/indaco-capital) — VC Fund, 2 deals together
- [Oceanpine Capital](https://shizune.co/investors/profile/oceanpine-capital) — VC Fund, 2 deals together
- [ZJU Joint Innovation Investment](https://shizune.co/investors/profile/zju-joint-innovation-investment) — VC Fund, 2 deals together
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 1 deal together
- [Aurora Private Equity](https://shizune.co/investors/profile/aurora-private-equity) — VC Fund, 1 deal together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [HOWZAT Partners](https://shizune.co/investors/profile/howzat-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund

## Featured in investor lists
- [Travel Investors in Asia](https://shizune.co/investors/travel-investors-asia)
- [Travel Investors in China](https://shizune.co/investors/travel-investors-china)
- [Travel VC Funds in China](https://shizune.co/investors/travel-vc-funds-china)
- [Travel VC Funds in Asia](https://shizune.co/investors/travel-vc-funds-asia)
- [Internet Investors in Taiwan](https://shizune.co/investors/internet-investors-taiwan)
- [Enterprise Investors in Taiwan](https://shizune.co/investors/enterprise-investors-taiwan)

## FAQ

### What does Jiuyou Capital invest in?

Jiuyou Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Jiuyou Capital's check size?

Jiuyou Capital typically joins rounds of $14M–$43M at Series A, $2.8M–$41M at Series B and $2.8M–$142M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jiuyou Capital participates in.

### How do I contact Jiuyou Capital?

Public channels for Jiuyou Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Jiuyou Capital?

The team at Jiuyou Capital includes Sun Yi (Managing partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co